Replimune stock.

Real time Replimune Group (REPL) stock price quote, stock graph, news & analysis.Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) saw some unusual options trading on Friday. Traders purchased 5,463 call options on the stock. This is an increase of approximately 87% ...About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell …View the basic REPL option chain and compare options of Replimune Group, Inc. on Yahoo Finance.WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its registration-directed global randomized Phase 2 clinical trial of RP1 in combination with …

REPL Stock 12 Months Forecast. $57.33. (396.79% Upside) Based on 4 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $57.33 with a high forecast of $70.00 and a low forecast of $42.00. The average price target represents a 396.79% change from the last price of $11.54.

WOBURN, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application for its lead …

We would like to show you a description here but the site won’t allow us.US76029N1063. Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA. Show more.Replimune Group Inc. is doing cutting-edge work in the field of new cures for cancer. They are "pioneering a novel class of tumor-directed oncolytic immunotherapies (TDOI) designed to kill the ...The shares of common stock and the pre-funded warrants described above are being offered by Replimune pursuant to its shelf registration statement on Form S-3, including a base prospectus, that ...

Dec 7, 2022 · In addition, Replimune intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock from Replimune at the public offering price ...

1,703.30 -8.20(-0.48%) Crude Oil 76.65 -0.52(-0.67%) Gold 1,943.70 +6.00(+0.31%) Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. …

Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsView the latest Replimune Group Inc. (REPL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Using Order Flow and Market Profile to Trade Stocks. 0. 1. Love in every #TradingView. 50M+. Traders and investors use our platform.If you are looking for stocks with good return, Replimune Group Inc stock can be a bad, high-risk 1-year investment option. Replimune Group Inc real time quote is equal to 10.390 USD at 2023-11-25, but your current investment may be devalued in the future.Nov 3, 2023 · WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or ... REPL. About Replimune Group Inc. Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer ...Shares of Replimune Group Inc. (REPL) surged more than 46% to touch a new high of $46.28 in intraday trading on Wednesday after an analyst at Roth Capital Tony Butler hiked his price target on the ...

Cannabis Stocks. 164.71k followers • 21 symbols +0.34% Watchlist by Yahoo Finance. Follow this list to discover and track the stock of publicly traded companies with exposure to cannabis.31 Jul 2023 ... Replimune will supply Incyte with RP1 for the study and share equally in the costs of the study. About RP1. RP1 is Replimune's lead oncolytic ...19 Sep 2023 ... The inducement awards consist of a non-qualified stock option to purchase 125,000 shares of the Company's common stock and restricted stock ...Replimune | Stock Quote & Chart Investors & Media Overview Events and Presentations Press Releases Corporate Governance Financials & Filings Stock Information Publications Email Alerts Investor Contact Select Page Stock Quote & Chart Stock Quote & Chart Historical Price Analyst Coverage Change Volume Today's Open Previous Close Today's High Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.

Barclays has chosen Biomea Fusion (BMEA), Replimune (REPL), Syndax (SNDX) and Iovance (IOVA) as its top picks in the small and mid-cap oncology space for the latter half of 2023.

WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the grant of inducement equity awards to Emily Hill, the Company’s newly appointed Chief Financial Officer.Replimune will supply Incyte with RP1 for the study and share costs. ... Research and development expenses included $3.3 million in stock-based compensation expenses for the first quarter ended ...Replimune Group is now considered extended and out of buy range after clearing a 20.23 buy point in a first-stage cup with handle.See if the stock forms a new pattern or follow-on buying ...During the last session, Replimune Group Inc (NASDAQ:REPL)’s traded shares were 0.83 million, with the beta value of the company hitting 1.46. At the end of the trading day, the stock’s price was $11.71, reflecting an intraday gain of 4.74% or $0.53. The 52-week high for the REPL share is $29.52, that puts it down -152.09 from that peak ...Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …The average price recommended by analysts for Replimune Group Inc is $48.44, which is significantly higher than the current market price. This suggests that there is room for the stock price to increase, according to analysts’ predictions. The company has also been involved in the development of a treatment for cutaneous squamous cell ...

According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.

Oct 1, 2021 · Replimune stock traded as low as $27.66 on August 26th, marking a near round trip from before its SITC presentation. There is plenty of competition in the oncolytic immunonocology space, but with ...

PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …Nov 13, 2023 · Replimune Group Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-3.531 per share for the current fiscal year. Replimune Group Inc does not currently pay a dividend. Today's Daily Dose brings you news about AnaptysBio's generalized pustular psoriasis trial results, Cyclerion discontinuing its Sickle Cell Disease drug program, FDA approving the first drug for Ebola, analyst's new price target of Replimune stock, and Vertex halting its phase II study of VX-814 in patients with alpha-1 antitrypsin deficiency.Replimune will have responsibility for operationalizing these clinical trials. ... the Company closed on an offering of common stock and pre-funded warrants raising approximately $259 million in ...PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory …In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share ...

The Replimune Group Inc. stock price fell by -1.82% on the last day (Wednesday, 29th Nov 2023) from $11.53 to $11.32.During the last trading day the stock fluctuated 6.13% from a day low at $11.26 to a day high of $11.95.The price has been going up and down for this period, and there has been a 0.89% gain for the last 2 weeks.BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of …Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 11.71 +0.53 (+4.74%) At close: 04:00PM EST 11.71 0.00 (0.00%) After hours: 04:20PM EST 1d 5d 1m... Today's Daily Dose brings you news about AnaptysBio's generalized pustular psoriasis trial results, Cyclerion discontinuing its Sickle Cell Disease drug program, FDA approving the first drug for Ebola, analyst's new price target of Replimune stock, and Vertex halting its phase II study of VX-814 in patients with alpha-1 antitrypsin deficiency.Instagram:https://instagram. general dynamics stock dividenddividend announcements todaybdo markettesla motors inc investor relations Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death … art investment stockbest broker app In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 1,436,172 shares of its common stock from Replimune at the public offering price, less the ... nucor corporation stock Replimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer.Replimune Group Stock (NASDAQ:REPL), Quotes and News Summary - Benzinga - – –% - – –% - – –% - – –% - – –% - – –% - – –% Replimune Group Inc …